Headline
The latest stories from AHA Today.
The Institute for Healthcare Improvement’s National Steering Committee for Patient Safety, whose members include the AHA and its American Organization for Nursing Leadership, released a national action plan to accelerate patient safety progress across the care continuum.
A new study demonstrates the cost to the U.S. health care system from an anti-competitive tactic known as “product hopping,” which involves a brand name drug company moving patients to a new reformulated version of a drug when an existing drug’s exclusivity is close to expiring.
President Trump issued a new executive order that seeks to lower prescription drug prices. The order directs the Secretary of Health and Human Services to test a “most-favored-nation” pricing model for Part B, and some Part D, drugs.
The Oregon Association of Hospitals Research & Education Foundation has established a relief fund to support hospital workers affected by the state’s wildfires, as well as future disasters.
To ease the continued strain on the N95 supply chain and Strategic National Stockpile, the National Institute for Occupational Safety and Health is considering whether the federal government should buy and deploy elastomeric half-mask respirators in health care settings and emergency medical…
The Department of Labor released a temporary rule revising regulations implementing certain paid leave provisions through Dec. 31 under the Families First Coronavirus Response Act.
The AHA and Aligning for Health Sept. 24 at 3 p.m. ET will host a webinar detailing how hospitals and health systems have been working to better identify and address health, social and community needs.
A Centers for Disease Control and Prevention study revealed that adults with positive SARS-CoV-2 test results were approximately twice as likely to have reported dining at restaurants within 14 days of developing symptoms compared with those whose test results were negative.
A new Centers for Disease Control and Prevention study is revealing the extent to which adults are bypassing medical care because of their COVID-19-related concerns.
The National Institutes of Health announced the launch of two of three planned, worldwide phase 3 clinical trials of varying types of blood thinners to treat adults with COVID-19.